Chronic Spontaneous Urticaria With Inadequate Response To Antihistamines Therapeutics
1. Rhapsido patent expiration
Treatment: Treatment of chronic autoimmune urticaria; Treatment of chronic spontaneous urticaria
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9512084 | NOVARTIS | Amino Pyrimidine Derivatives |
Nov, 2034
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10457647 | NOVARTIS | Amino Pyrimidine Derivatives |
Nov, 2034
(8 years from now) | |
| US12419889 | NOVARTIS | Methods Of Treating Chronic Spontaneous Urticaria Using A Bruton'S Tyrosine Kinase Inhibitor |
Jan, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 30, 2030 |
Drugs and Companies using REMIBRUTINIB ingredient
NCE-1 date: 30 September, 2029
Market Authorisation Date: 30 September, 2025
Dosage: TABLET
More Information on Dosage
RHAPSIDO family patents
